UK patient first to contract vCJD via blood transfusion

Sibbald, Barbara
March 2004
CMAJ: Canadian Medical Association Journal;3/30/2004, Vol. 170 Issue 7, p1087
Academic Journal
journal article
Deals with a report about the death of a patient in Great Britain due to variant Creutzfeldt-Jakob (vCJD) disease which is likely the first documented transfusion-related transmission. Results of several studies conducted to determine the cause of the disease; Information on vCJD; Comment from Heather Hume, medical director of Canadian Blood Services, on the transfusion case.


Related Articles

  • The quandary of Creutzfeldt-Jakob disease. Larke, Bryce // CMAJ: Canadian Medical Association Journal;10/06/98, Vol. 159 Issue 7, p789 

    Editorial. Questions the controversy in Canada over whether to notify recipients of blood products that may have been contaminated with Creutzfeldt-Jakob disease (CJD). Rarity of the disease; Lack of direct evidence of CJD transmission through blood transfusion; Why the medical community is...

  • Innocent white blood cells in sporadic Creutzfeldt-Jakob disease? Soon-Tae Lee; Jae-Kyu Roh // Laboratory Investigation (00236837);Jun2009, Vol. 89 Issue 6, p612 

    The article offers the author's views on a study related to white blood cells in sporadic Creutzfeldt-Jakob disease (sCJD). He says that the study is doubtful on the necessity of leukodepletion to prevent prion transmission from sCJD patients. He states that the concerns of the study are still...

  • Notifying patients exposed to blood products associated with Creutzfeldt Jakob disease: theoretical risk for real people. King, Susan M.; Watson, Heather; Heurter, Helen; Ricketts, Maura; Elsaadany, Susie // CMAJ: Canadian Medical Association Journal;10/06/98, Vol. 159 Issue 7, p771 

    Describes a survey taken to determine the views of patients and parents of blood transfusion recipients. Their notification that they or their child had received blood products that posed a hypothetical risk of transmission of Creutzfeldt-Jakob disease; Recall of blood products by Canadian Red...

  • Recipients of blood or blood products "at vCJD risk" Bird, Sheila M // BMJ: British Medical Journal (International Edition);1/17/2004, Vol. 328 Issue 7432, p118 

    Discusses steps needed to define the rights and responsibilities of recipients of "at vCJD (Creutzfeldt-Jakob disease) risk" blood and blood products. Steps to protect the rights of recipients and of the public; Steps to prevent further human to human transmission; First probable victim of...

  • Standardized surveillance of prion diseases in resource-poor settings is crucial for individual patient-care as well as for decision-making of healthcare authorities. Karch, André // Journal of Neurosciences in Rural Practice;Jan-Mar2015, Vol. 6 Issue 1, p4 

    An introduction to the journal is presented in which the editor discusses the series of eight Creutzfeldt-Jakob disease (CJD) patients in a tertiary care hospital in Bangalore, India.

  • Variant Creutzfeld-Jakob disease (vCJD).  // Weekly Epidemiological Record;11/24/2000, Vol. 75 Issue 47, p377 

    Focuses on the precautionary measures against the risk of transmission of Variant Creutzfeldt-Jacob disease (vCJD) by blood transfusion in Great Britain. Cause of vCJD; Risk of vCJD transmission by transfusion; Advantages of implementing the precautionary measures; Need of government commitment...

  • Blood transfusion risk: Protecting against the unknown. Barbara, John; Flanagan, Peter // BMJ: British Medical Journal (International Edition);03/07/98, Vol. 316 Issue 7133, p717 

    Editorial. Focuses on the potential blood transfusion risk posed by a variant Creutzfeldt-Jakob disease in Great Britain. Evidence of risk; Measures identified by the Committee on Safety of Medicines to address the issue; Resource implications of the precautionary measures.

  • CJD experts warn of transfusion dangers.  // Nature;4/3/1997, Vol. 386 Issue 6624, p429 

    Reports on the recommendation that blood from people at risk from transmissible spongiform encephalopathies should not be used for transfusions. The recommendations of experts on Creutzfeldt-Jakob disease.

  • CONSULT STAT. Pritchard, Vicki; Coleman, Deborah A.; Ballou, Kathleen; DaSilva, Doris; Lee, Richard W.; Gardner, Robin; Baudler, Alan J.; Gaylord, Jill; Kutcher, Joyce // RN;Jun87, Vol. 50 Issue 6, p69 

    Answers several questions related to nursing. Need for patients with suspected Creutzfeldt-Jakob disease to be put in isolation; Methodology used to evaluate a person's cell-mediated immune response; Danger of using a standard intravenous infusion pump for transfusing blood or blood products.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics